Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 2;11(1):89.
doi: 10.1186/s13014-016-0663-1.

Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma

Yaoru Huang  1   2 , Shang-Wen Chen  3   2 , Ching-Chao Fan  4 , Lai-Lei Ting  1   2 , Chia-Chun Kuo  1   2 , Jeng-Fong Chiou  5   6
Affiliations

Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma

Yaoru Huang et al. Radiat Oncol. .

Abstract

Background: Few data are available on the tolerance of reirradiation in patients with hepatocellular carcinoma (HCC). This study determined the clinical parameters contributing to the development of radiation-induced liver disease (RILD).

Methods: We included 36 patients with HCC who received 2 courses of radiotherapy (RT) to the liver. Using α/β = 15 for tumor and α/β =8 for normal liver tissue for biologically equivalent doses in 2 Gy fractions, mean cumulative to the hepatic tumor and normal liver were 87.7 Gy15 and 31.1 Gy8, respectively. Hepatic toxicities were classified according to the Common Terminology Criteria for Adverse Events, Version 4.0. Clinical data, including liver function test results, radiological study findings, and RT parameters before and after both courses of RT were retrieved for analysis. Using multivariate analysis, logistic regression was used to identify the predictors of RILD, and Cox regression was performed to explore the prognostic factors for overall survival (OS).

Results: Thirteen patients (36 %) developed RILD after reirradiation. Nine of them died because of progressive liver failure without evidence of tumor progression and were categorized to have lethal RILD. A pretreatment Child-Turcotte-Pugh (CTP) score ≥6 was the only predictor of RILD [odds ratio (OR): 15.83, p = 0.001] and lethal RILD [OR: 72.56, p = 0.005]. In addition, a CTP score ≥6 and the presence of portal vein tumor thrombosis before reirradiation were 2 prognostic factors for OS.

Conclusion: Despite a limited sample size, residual liver function using a preirradiation CTP score ≥6 is a clinical parameter associated with an increased risk of RILD in patients requiring hepatic reirradiation.

Keywords: Hepatocellular carcinoma; Irradiation; Prognostic factor; Radiation-induced liver disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival according to the occurrence of RILD, pre-reirradiation CTP score, and presence of PVTT. Abbreviation: RILD, radiation-induced liver disease; CTP, Child-Turcotte-Pugh; PVTT, portal vein tumor thrombosis
See this image and copyright information in PMC

References

    1. Dawson LA, Guha C. Hepatocellular carcinoma: radiation therapy. Cancer J. 2008;14:111–116. doi: 10.1097/PPO.0b013e31816a0e80. - DOI - PubMed
    1. Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys. 2012;87:22–32. doi: 10.1016/j.ijrobp.2012.08.043. - DOI - PubMed
    1. Furuse J, Ishi H, Nagase M, et al. Adverse hepatic events caused by radiotherapy for advanced hepatocellualr carcinoma. J Gastroenterol Hepatol. 2005;20:1512–1518. doi: 10.1111/j.1440-1746.2005.03916.x. - DOI - PubMed
    1. Dawson LA, Haken R. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005;15:279–283. doi: 10.1016/j.semradonc.2005.04.005. - DOI - PubMed
    1. Dawson LA, Normolle D, Balter J, et al. Analysis of radiation-induced liver disease using the Lyman NTCP models. Int J Radiat Oncol Biol Phys. 2002;53:810–821. doi: 10.1016/S0360-3016(02)02846-8. - DOI - PubMed